Drug intelligence / Profile preview

T6991-2

Development stage: Preclinical
Modality: Peptides

Overview

T6991-2 is a peptide derived from the apoE CT domain, which has been studied for its potential in enhancing cellular cholesterol efflux and improving insulin sensitivity. It is administered subcutaneously and has shown favorable effects in models of diabetes and cardiovascular disease by improving glucose metabolism without affecting body weight or β-cell function.

Beyond the preview

Go deeper on T6991-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T6991-2.

Explore the full profile